跳至主要内容
临床试验/NCT00306397
NCT00306397已完成4 期

Open, Single Centre, Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression

University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2005年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
100
试验地点
1
主要终点
Allograft function

研究概览

简要总结

The main purpose of this study is to investigate, whether a steroid free immunosuppressive treatment is a valuable alternative in the treatment of de novo kidney transplant recipients and if it is possible to withdraw calcineurin inhibitors after 3 months.

详细描述

Protocol synopsis Title An open, single centre, pilot study to investigate a steroid free immunosuppressive regimen for de novo renal transplant recipients followed by a two arm randomization to a calcineurin inhibitor containing and a calcineurin inhibitor free maintenance immunosuppression after three months. Study code Sterfree pilot study Project phase An open, single centre, one arm study followed by a 1:1 randomized, parallel group, comparative study after three months. Study objectives To obtain preliminary information on the efficacy and safety of a rapamycin / sodium-mycophenolate (Myfortic) / tacrolimus regimen in the absence of steroids for the prevention of acute rejection following renal transplantation. To compare a low dose tacrolimus / rapamycin / sodium-mycophenolate (Myfortic) regimen to a rapamycin / sodium-mycophenolate regimen in patients without evidence of acute rejection after three months.

Efficacy:

Primary endpoint

  • Plasma creatinine (and creatinine clearance (Cockcroft)) Secondary endpoints
  • Incidence of first acute rejections and total number of acute rejections
  • Total number of anti-rejection treatments
  • Patients successfully withdrawn from calcineurin inhibitor at three months
  • Graft survival
  • Patient survival

Safety:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • adult patients with end stage kidney disease suitable for primary renal transplantation or retransplantation
  • patients receiving a graft from a living related, living unrelated or brain-death donor

排除标准

  • patients with a low or high immunological risk constellation

研究组 & 干预措施

A

Active Comparator

Rapamycin - MMF after 3 months

干预措施: Rapamycin (Drug)

B

Active Comparator

Low dose tacrolimus - MMF - Rapamycin after 3 months

干预措施: Rapamycin (Drug)

结局指标

主要结局

Allograft function

时间窗: 6 months

次要结局

  • Patients successfully withdrawn from calcineurin inhibitor after three months(3 months)
  • Graft survival(6 months)
  • Patient survival(6 months)

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other

研究点 (1)

Loading locations...

相似试验